A preclinical re-evaluation of the safety profile of tolcapone.
Borroni
E
E
Pharmaceutical Division, Preclinical CNS Research, F. Hoffmann-La Roche Ltd, Basel, Switzerland. edilio.borroni@roche.com
Cesura
A M
AM
Gatti
S
S
Gasser
R
R
D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects*; D001577:Benzophenones / Q000009:adverse effects*; D004341:Drug Evaluation; D006801:Humans; D008099:Liver / Q000187:drug effects; D008928:Mitochondria / Q000378:metabolism; D009596:Nitrophenols; D010101:Oxygen Consumption / Q000187:drug effects; D017382:Reactive Oxygen Species / Q000378:metabolism; D012449:Safety; D000077867:Tolcapone
D000978:Antiparkinson Agents; D001577:Benzophenones; D009596:Nitrophenols; D017382:Reactive Oxygen Species; D000077867:Tolcapone